w27, you are right. Am hoping will get it right. I found some promising comments from bioshares analysts and from Greg Collier in the below link. several positives building up momentum as I see it.. the capital raising is almost done which should cover us for some years funding. the 3M collaboration is an excellent move. 3 trials underway. Since may last year we have the best in the business Greg on this one(suggest to those who want to know more to google greg collier to know how good he is). Just need to be patient on this.
of the comments in the link..this one is most interesting! " Bioshares analysts said while Invion carried risk, the collaboration was “a big step forward”. “The development of inhaled versions (two drugs) should result in better drugs being made which should ultimately be far more attractive to larger pharmaceutical companies on the hunt for new products,”
ps: DYOR. not a financial advise link: http://www.couriermail.com.au/business/invion-issues-then-retracts-bankruptcy-notices-against-former-execs/story-fnihsps3-1226857461258
the specific comments I liked... "
“People see there’s a lot of upside,” Invion CEO Greg Collier said, arguing Invion had three products under trial but only a $40 million market capitalisation.
He highlighted a recent collaboration with 3M to create inhaled versions of treatments, including targeting asthma. “You get the drug to the area that you want to work more efficiently,” he said.
Bioshares analysts said while Invion carried risk, the collaboration was “a big step forward”. “The development of inhaled versions (two drugs) should result in better drugs being made which should ultimately be far more attractive to larger pharmaceutical companies on the hunt for new products,” Bioshares said.
The accounts listed related party deals — Invion will pay a $500,000 license fee to a company to commercialise a substance. Invion’s chief medical officer Mitchell Glass had worked on that drug in the 1990s and is a substantial shareholder in the company doing the deal.
Invion also has hired a clinical trial management operation of Numoda, while a Numoda affiliate invests up to $2 million in Invion shares. Dr Collier rejected any conflict of interest between the two entities, saying the two Numoda entities operated separately. "
IVX Price at posting:
7.7¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)